Venus Medtech's Transcatheter Pulmonary Valve Debuts in Europe, Marking the Start of Global Clinical Trial

LONDON and HANGZHOU, China-- Venus P, the transcatheter pulmonary valve developed in-house by Hangzhou, China-based medical instrument producer Venus Medtech (Hangzhou) Inc., was successfully implanted in a European patient in London on September 13th, 2016. Venus Medtech is the sole owner of the intellectual property rights to the valve. This is not only a milestone for the official launch of CE Mark certification clinical trials being undertaken for Venus Medtech's Venus P-Valve, but also marks the start of a journey for the entry of China-made transcatheter valve in the developed markets of the U.S. and Europe.

 

Prof. Shakeel Qureshi is the Principal Investigator (PI) for the CE Mark certification clinical trial in Europe, the first phase of the clinical trials of which involved 6 locations, and 80 to 100 patients across Europe, including a few locations outside of the continent. This is the first formal set of clinical trials in multiple locations across Europe that used China-made transcatheter valves.